Plasma P-selectin is an early marker of thromboembolism in COVID-19
Plasma P-selectin is an early marker of thromboembolism in COVID-19
Abstract Coagulopathy and thromboembolism are known complications of SARS-CoV-2 infection. The mechanisms of COVID-19-associated hematologic complications involve endothelial cell and platelet dysfunction and have been intensively studied. We leveraged a prospectively collected acute COVID-19 biorepository to study the association of plasma levels of a comprehensive list of coagulation proteins with the occurrence of venous thromboembolic events (VTE). We included in our analysis 305 subjects with confirmed SARS-CoV-2 infection who presented to an urban Emergency Department with acute respiratory distress during the first COVID-19 surge in 2020; 13 (4.2%) were subsequently diagnosed with venous thromboembolism during hospitalization. Serial samples were obtained and assays were performed on two highly-multiplexed proteomic platforms. Nine coagulation proteins were differentially expressed in patients with thromboembolic events. P-selectin, a cell adhesion molecule on the surface of activated endothelial cells, displayed the strongest association with the diagnosis of VTE, independent of disease severity (p=0.0025). This supports the importance of endothelial activation in the mechanistic pathway of venous thromboembolism in COVID-19. P-selectin together with D-dimer upon hospital presentation provided better discriminative ability for VTE diagnosis than D-dimer alone.
Goldberg Marcia B.、Fenyves B¨￠nk G.、Kays Kyle R.、Hacohen Nir、Mehta Arnav、MGH COVID-19 Collection & Processing Team、Filbin Michael R.
Department of Medicine, Harvard Medical School||Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard||Center for Bacterial Pathogenesis, Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital||Department of Microbiology, Harvard Medical SchoolDepartment of Emergency Medicine, Massachusetts General Hospital||Department of Molecular Biology, Semmelweis University||Department of Emergency Medicine, Semmelweis UniversityDepartment of Emergency Medicine, Massachusetts General HospitalDepartment of Medicine, Harvard Medical School||Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard||Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General HospitalDepartment of Medicine, Harvard Medical School||Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard||Department of Medical Oncology, Dana-Farber Cancer Institute||Massachusetts General Hospital Cancer Center, Department of Medicine, Massachusetts General HospitalDepartment of Emergency Medicine, Massachusetts General Hospital||Broad Institute of Massachusetts Institute of Technology (MIT) and Harvard||Department of Emergency Medicine, Harvard Medical School
医学研究方法基础医学临床医学
Goldberg Marcia B.,Fenyves B¨￠nk G.,Kays Kyle R.,Hacohen Nir,Mehta Arnav,MGH COVID-19 Collection & Processing Team,Filbin Michael R..Plasma P-selectin is an early marker of thromboembolism in COVID-19[EB/OL].(2025-03-28)[2025-05-23].https://www.medrxiv.org/content/10.1101/2021.07.10.21260293.点此复制
评论